Not yet recruitingPhase 2NCT05484375

Capecitabine Plus Toripalimab Maintenance Therapy in Metastatic Nasopharyngeal Carcinoma After First-line Treatment

Studying Nasopharyngeal carcinoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Principal Investigator
Yin Wen-Jing
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Intervention
Capecitabine plus toripalimab(drug)
Enrollment
40 target
Eligibility
18-65 years · All sexes
Timeline
2022 – 2029

Collaborators

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Hunan Cancer Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05484375 on ClinicalTrials.gov

Other trials for Nasopharyngeal carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Nasopharyngeal carcinoma →

← Back to all trials